Lucy Burr

Associate Professor Lucy Burr is an Associate Professor in the School of Medicine at the University of Queensland (UQ), with dual roles as Director of Respiratory, Sleep, and Cystic Fibrosis Medicine at Mater Hospital, Brisbane, and Group Leader of the Respiratory Clinical Trials Unit at Mater Research. She holds leadership positions in national and international organizations, including chairing the Australian Bronchiectasis Consortium and serving on the Thoracic Society of Australia and New Zealand (TSANZ) national board. Her research focuses on cystic fibrosis, bronchiectasis, respiratory infections, and translational clinical trials, with over 1500 citations in the last five years. She supervises multiple PhD students and leads clinical trials spanning CF therapeutics, pulmonary hypertension, and infectious diseases.

Education:

• Bachelor of Medicine and Surgery, King's College London
• PhD in Respiratory Diseases (UQ, 2017)
• Fellowships: Royal Australasian College of Physicians and TSANZ
• Leadership Diploma, Mater Education

Research Interests:

Burr’s work bridges clinical practice and research, emphasizing chronic respiratory diseases, clinical trial design, and microbiological mechanisms. Key areas include CFTR modulator therapies, macrolide use in bronchiectasis, and the role of IL-22 in metabolic and inflammatory pathways. She manages the David Serisier Research Biobank and leads pharmaceutical studies from Phase 1b to Phase 4.

Grants & Awards:

• Total grants managed: $4.3 million (including NHMRC Ideas Grant and MRFF grants)
• Peer-reviewed grants ($1.3M) focusing on biobanked samples and therapeutic trials
• Recognized as top 1.8% global expert in Cystic Fibrosis and 2.2% in Bronchiectasis (Expertscape, 2024)

Advising & Labs:

Burr mentors 5 PhD students and trains medical residents. Her lab collaborates on studies involving lung microbiology, drug metabolism, and metabolic disease mechanisms. She chairs the TSANZ annual scientific meetings and contributes to global guidelines for respiratory care, including the National COVID-19 Clinical Evidence Taskforce.